base metals investing Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
base metals investing Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
base metals investing Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
base metals investing Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
base metals investing Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer
base metals investing Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
base metals investing Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
base metals investing Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
The Crushed Pile in Nevada: How a Forgotten 1989 Gold Heap Is Becoming One of America's Few Near-Term Antimony Solutions
